VANCOUVER, BC – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate immune system, has reported positive genetic analyses of their recently completed Phase 2 clinical studies in Crohn’s Disease (CD) and Ulcerative Colitis (UC).
According to the company, these findings suggest that, for the first time in the field of inflammatory bowel disease (IBD), personalized medicine and the application of genetic testing may identify patients highly likely to respond and go into remission with treatment.
The analyses identified common IBD-related genotypes with a high likelihood of response to SSI, suggesting that genetic testing may identify a large subset of CD patients (representing approximately 60 per cent of the CD population) with a greater than 80 per cent likelihood of responding to QBECO treatment, the large majority of which achieved remission on SSI treatment.
“We are very excited about the possibility of identifying CD and UC patients highly likely to respond to SSI treatment, which would substantially de-risk future trials and be an important advance for patients who currently face the uncertainty of knowing whether current immunosuppressive IBD treatments, which can be associated with significant side effects, will work for them or not,” Dr. Hal Gunn, CEO of Qu Biologics, stated.
Dr. Shirin Kalyan, Qu’s director of Scientific Innovation, adds that, “Unlike current IBD treatments that suppress immune function, we believe that SSIs, which restore innate immune function, treat the underlying cause of IBD. Consequently, unlike other treatments, we were able to identify IBD-related genotypes highly responsive to SSI therapy.”
Based on the promising results of the study in CD, the company says that a follow-on Phase 2 study in moderate to severe CD is planned to confirm these findings. Study initiation is anticipated in late 2017.
If the genetic analysis results are confirmed in follow-on studies, Qu Biologics’ QBECO SSI has the potential to become first-line therapy for a majority of IBD patients.